(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged abiraterone, AKT inhibitor, biomarkers, clinical trial, genetic markers, Institute of Cancer Research London, ipatasertib, IPATential150 trial, metastatic castration-resistant prostate cancer mCRPC, overall survival, personalized medicine, PIK3CA/AKT1/PTEN pathway, Professor Johann de Bono, PTEN gene, Roche, sequencing techniques, synthetic lethality, targeted therapy, UK patients
(IN BRIEF) Scientists at the Institute of Cancer Research in London have developed an innovative algorithm named SYLVER, which analyzes data from over 9,300 patients to identify synthetic lethal gene pairs that cancer cells depend on for survival. Unlike previous … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged 300 patients, 9, algorithm, backup genes, BRCA mutations, Breast Cancer Now, buffering mechanism, Cancer, Cancer Genome Atlas, Cancer Research UK, Dr Hattie Brooks, Dr Simon Vincent, Dr Syed Haider, inhibitor drugs, Institute of Cancer Research, London, NIHR Biomedical Research Centre, Professor Chris Lord, protein targets, Royal Marsden NHS Foundation Trust, SYLVER, synthetic lethality, targeted therapies, tumour-suppressor genes, Walk the Walk
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?